Diabetes and COVID-19; a Review of Possible Mechanisms

被引：5

作者：

Moradi-marjaneh, Reyhaneh ^{[1
]}

Asgharzadeh, Fereshteh ^{[2
]}

Khordad, Elnaz ^{[3
]}

Marjaneh, Mahdi Moradi ^{[4
]}

机构：

[1] Gonabad Univ Med Sci, Dept Basic Sci, Fac Med, Gonabad, Iran

[2] Mashhad Univ Med Sci, Sch Med, Dept Physiol, Mashhad, Razavi Khorasan, Iran

[3] Torbat Heydariyeh Univ Med Sci, Sch Paramed Sci, Dept Physiol, Torbat Heydariyeh, Iran

[4] Imperial Coll London, Fac Med, Dept Infect Dis, London, England

来源：

CURRENT PHARMACEUTICAL DESIGN | 2021年 / 27卷 / 21期

关键词：

Diabetes; COVID-19; mechanism; risk factor; prognosis; review; SARS-CoV-2; CORONAVIRUS; MELLITUS; RECEPTOR; ACE2; PREVALENCE;

D O I：

10.2174/1381612827666210303141846

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Coronavirus disease 2019 (SARS-CoV-2) (COVID-19) has recently raised worldwide public health concerns. The available data on COVID-19 in patients with diabetes is limited but generally indicate that there is an increased risk of developing COVID-19 infection in diabetic patients, which ultimately impacts the overall patient's survival. Various aspects might be involved; however, the exact mechanisms and interrelationships between diabetes and the novel COVID-19 have not yet been fully elucidated. This review summarizes the possible mechanisms by which present diabetes predispose individuals to COVID-19 infection, modulates the host viral interactions and increases the risk of mortality. We hope this review can provide beneficial information for further studies and contribute to improved disease management of diabetic patients with COVID-19.

引用

页码：2522 / 2527

页数：6

共 78 条

[1] Pulmonary function changes in diabetic lung [J].

Abd El-Azeem, I. Amal ;

Hamdy, Gehan ;

Amin, Mohamed ;

Rashad, Alaa .

EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2013, 62 (03) :513-517

[2]

Ahmed MS, 2008, J RESP DIS, V29

[3] Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity [J].

Ajjan, Ramzi A. ;

Gamlen, Toby ;

Standeven, Kristina F. ;

Mughal, Salihah ;

Hess, Katharina ;

Smith, Kerrie A. ;

Dunn, Emma J. ;

Anwar, M. Maqsud ;

Rabbani, Naila ;

Thornalley, Paul J. ;

Philippou, Helen ;

Grant, Peter J. .

BLOOD, 2013, 122 (01) :134-142

[4]

[Anonymous], RAND CONTR TRIAL EFF

[5]

Ardigo Diego, 2004, Current Drug Targets - Inflammation and Allergy, V3, P455, DOI 10.2174/1568010042634488

[6] Practical recommendations for the management of diabetes in patients with COVID-19 [J].

Bornstein, Stefan R. ;

Rubino, Francesco ;

Khunti, Kamlesh ;

Mingrone, Geltrude ;

Hopkins, David ;

Birkenfeld, Andreas L. ;

Boehm, Bernhard ;

Amiel, Stephanie ;

Holt, Richard I. G. ;

Skyler, Jay S. ;

DeVries, J. Hans ;

Renard, Eric ;

Eckel, Robert H. ;

Zimmet, Paul ;

George Alberti, Kurt ;

Vidal, Josep ;

Geloneze, Bruno ;

Chan, Juliana C. ;

Ji, Linong ;

Ludwig, Barbara .

LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (06) :546-550

[7] COVID-19 in people living with diabetes: An international consensus [J].

Caballero, A. E. ;

Ceriello, A. ;

Misra, A. ;

Aschner, P. ;

McDonnell, M. E. ;

Hassanein, M. ;

Ji, L. ;

Mbanya, J. C. ;

Fonseca, V. A. .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (09)

[8]

Chen X, 2020, HYPERTENSION DIABETE, DOI [10.1101/2020.03.22.20040774, DOI 10.1101/2020.03.22.20040774]

[9] COVID-19 and diabetes: The why, the what and the how [J].

Cuschieri, Sarah ;

Grech, Stephan .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (09)

[10] Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review [J].

Dambha-Miller, Hajira ;

Albasri, Ali ;

Hodgson, Sam ;

Wilcox, Christopher R. ;

Khan, Shareen ;

Islam, Nazrul ;

Little, Paul ;

Griffin, Simon J. .

BMJ OPEN, 2020, 10 (09)

← 1 2 3 4 5 6 7 8 →